Welcome to our dedicated page for Bio Rad Labs news (Ticker: BIO), a resource for investors and traders seeking the latest updates and insights on Bio Rad Labs stock.
Bio-Rad Laboratories, Inc. (BIO) delivers essential innovations in clinical diagnostics and life science research through its global operations. This dedicated news hub provides investors and industry professionals with timely access to official announcements, financial updates, and scientific advancements.
Discover comprehensive collection of press releases covering quarterly earnings, regulatory milestones, product launches, and strategic partnerships. Our curated feed ensures transparent access to BIO's operational developments across its dual focus areas: laboratory-quality diagnostic systems and cutting-edge research tools.
Key updates include innovations in digital PCR technology, quality control solutions for clinical testing, and advancements supporting biopharmaceutical development. Bookmark this page for direct access to primary-source information affecting BIO's market position and research impact.
Element Biosciences and Bio-Rad Laboratories have announced a partnership to advance RNA sequencing through the integration of Bio-Rad's SEQuoia RNA Sequencing Library Preparation portfolio with Element's AVITI™ Benchtop Sequencer. This collaboration aims to enhance RNA sequencing accuracy and efficiency, utilizing SEQuoia kits designed for various RNA inputs. The AVITI System offers unique capabilities, including two independent flow cells and up to 2 billion reads, ensuring high-quality data. Results from their collaboration will be presented at the AGBT General Meeting on February 9, 2023. This initiative positions both companies to deliver a cost-effective solution for genomic research.
Bio-Rad Laboratories, Inc. will report its financial results for Q4 and full year 2022 on February 16, 2023, post-market close. Management will host a conference call at 2 PM PT (5 PM ET) to discuss these results. Participants can dial 844-200-6205 in the U.S. or +1 929-526-1599 internationally, using access code: 143970. A live webcast will also be available on their website. Bio-Rad is recognized globally for developing and marketing life science and clinical diagnostic products, generating $2.9 billion in revenues as of 2021.
Bio-Rad Laboratories will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 4:30 p.m. Pacific Time. CEO Norman Schwartz will lead the company overview, followed by a Q&A with Andrew Last and Ilan Daskal, Bio-Rad's Executive Vice Presidents. The event will be available via a webcast on Bio-Rad's website.
Bio-Rad Laboratories (NYSE: BIO and BIO.B) announced that its management will participate in a Fireside Chat during the Credit Suisse 31st Annual Healthcare Conference on Tuesday, November 8, 2022, at 11:00 AM (PST). A live webcast will be accessible on the company's Investor Relations webpage at bio-rad.com. Bio-Rad, based in Hercules, California, is a leader in life science research and clinical diagnostics, with approximately 8,200 employees and $2.9 billion in revenue for 2021.
Bio-Rad Laboratories reported Q3 2022 net sales of $680.8 million, down 8.9% from Q3 2021. COVID-related revenue declined to $17 million from $57 million in the previous year. The Life Science segment saw a 14.9% decrease in net sales, while Clinical Diagnostics dipped 2.8%. The company posted a net loss of $164.2 million, or $5.52 per share, compared to net income of $3.9 billion or $129.96 per share in Q3 2021. The non-GAAP outlook for 2022 anticipates currency-neutral revenue growth at the high end of 1-2% guidance.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) will report its third-quarter 2022 financial results on October 27, 2022, after market close. A conference call discussing these results is scheduled for 2 PM Pacific Time the same day. Bio-Rad, a leader in life science research and clinical diagnostics, generated $2.9 billion in revenues for 2021 and employs approximately 7,900 individuals worldwide. Investors can access a live webcast via the 'Investor Relations' section of the company's website.
Bio-Rad Laboratories (NYSE: BIO) has announced the acquisition of Curiosity Diagnostics for up to $170 million, comprising $100 million in cash and $70 million in future milestones. Curiosity, based in Poland, is developing a rapid diagnostics PCR system for the molecular diagnostics market. This acquisition aims to enhance Bio-Rad's Clinical Diagnostics Group, expanding into near-patient molecular diagnostics. With Bio-Rad's extensive market presence and Curiosity's innovative technology, the deal is anticipated to improve product offerings and market reach.
Bio-Rad Laboratories (NYSE: BIO, BIO.B) reported Q2 2022 net sales of $691.1 million, down 3.5% year-over-year, with COVID-related revenue falling to approximately $33 million. Currency-neutral sales recorded a 0.5% increase. Life Science segment sales decreased by 3.5% to $322.4 million, while Clinical Diagnostics fell 3.3% to $367.8 million. A significant net loss of $927.2 million was reported versus a net income of $914.1 million in Q2 2021, largely due to equity securities valuation changes. The full-year outlook remains positive with expected revenue growth and an increased share repurchase program of $200 million.
Bio-Rad Laboratories, Inc. (NYSE: BIO) will report its financial results for Q2 2022 on July 28, 2022, after market close. A conference call is scheduled for 3 PM Pacific Time (6 PM Eastern Time) to discuss these results. Investors can participate by calling 844-200-6205 within the U.S. or +1 929-526-1599 internationally, access code: 715914. A live webcast will also be available.
FAQ
What is the current stock price of Bio Rad Labs (BIO)?
What is the market cap of Bio Rad Labs (BIO)?
